Use and Disposition of Collaborator Materials and ICD Materials Sample Clauses

Use and Disposition of Collaborator Materials and ICD Materials. The Parties agree to use Collaborator Materials and ICD Materials only in accordance with the Research Plan and Protocol(s), not to transfer these materials to third parties except in accordance with the Research Plan and Protocol(s) or as approved by the owning or providing Party, and, upon expiration or termination of the CRADA, to dispose of these materials as directed by the owning or providing Party.
Sample 1Sample 2Sample 3See All (30)
AutoNDA by SimpleDocs
Use and Disposition of Collaborator Materials and ICD Materials. Except as otherwise provided in this Article 3.3, Tthe Parties agree to use Collaborator Materials, Test Articles, and ICD Materials only in accordance with the Research Plan and Protocol(s), not to transfer these materials to third parties except in accordance with the Research Plan and Protocol(s) or as approved by the owning or providing Party, and, upon expiration or earlier termination of the CRADA, to dispose of these materials as directed by the owning or providing Party. ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(2), (4), (5) and (6) and 230.406 Notwithstanding the foregoing upon conclusion of the clinical studies enumerated under BB-MF 11139, within [***] following the Effective Date, ICD will execute a Notification of Change in Sponsorship, related FDA 1571 Forms, and any other documents required by law to transfer to Collaborator sponsorship of the following for the clinical development and commercialization of Licensed Products and Licensed Processes in the Licensed Field of Use, as those terms are defined in the Patent License Agreement — Exclusive License between PHS and Collaborator (HHS Ref. No. A-296-2009) executed contemporaneously with this CRADA (the “Patent License”):
Sample 1Sample 2
Use and Disposition of Collaborator Materials and ICD Materials. Except as otherwise provided in this Article 3.3, the Parties agree to use Collaborator Materials, Test Articles, and ICD Materials only in accordance with the Research Plan and Protocol(s), not to transfer these materials to third parties except in accordance with the Research Plan and Protocol(s) or as approved by the owning or providing Party, and, upon expiration or earlier termination of the CRADA, to dispose of these materials as directed by the owning or providing Party. Notwithstanding the foregoing upon conclusion of the clinical studies enumerated under BB-MF 11139, within thirty (30) days following the Effective Date, ICD will execute a Notification of Change in Sponsorship, related FDA 1571 Forms, and any other documents required by law to transfer to Collaborator sponsorship of the following for the clinical development and commercialization of Licensed Products and Licensed Processes in the Licensed Field of Use, as those terms are defined in the Patent License Agreement — Exclusive License between PHS and Collaborator (HHS Ref. No. A-296-2009) executed contemporaneously with this CRADA (the “Patent License”):
Sample 1Sample 2
Use and Disposition of Collaborator Materials and ICD Materials. Except as otherwise provided in this Section 3.3, Tthe Parties agree to use Collaborator Materials, Test Articles, and ICD Materials only in accordance with the Research Plan and Protocol(s), not to transfer these materials to any third parties except in accordance with the Research Plan and Protocol(s) or as approved by the owning or providing Party, and, upon expiration or earlier termination of this CRADA, to dispose of these materials as directed by the owning or providing Party. Notwithstanding the foregoing, within [***] following the Effective Date, ICD will execute a Notification of Change in Sponsorship, related FDA 1571 Forms, and any other documents required by law to transfer to Collaborator sponsorship of the following for the clinical development and commercialization of Licensed Products and Licensed Processes in the Licensed Field of Use, as those terms are defined in the Patent License Agreement — Exclusive License between PHS and Collaborator (HHS Ref. No. A-332-2007) executed contemporaneously with this CRADA (the “Patent License”):
Sample 1Sample 2

Related to Use and Disposition of Collaborator Materials and ICD Materials

  • Supply of Materials The following materials will be supplied by the department Name of Materials Rate. Place of delivery 1.

  • No Improper Use of Materials During his or her employment with the Company, Employee will not improperly use or disclose any Confidential Information or trade secrets, if any, of any former employer or any other person to whom Employee has an obligation of confidentiality, and Employee will not bring onto the premises of the Company any unpublished documents or any property belonging to any former employer or any other person to whom Employee has an obligation of confidentiality unless consented to in writing by that former employer or person.

  • Technical Information The Employer agrees to provide to the Union such information that is available relating to employees in the bargaining unit, as may be required by the Union for collective bargaining purposes.

  • Review of Materials During the term of this Agreement, Client shall ensure that all prospectuses, statements of additional information, registration statements, proxy statements, reports to shareholders, advertising and sales literature or other materials prepared for distribution to Fund shareholders or the public, which refer to the Subadviser in any way, prepared by employees or agents of Client or its affiliates are consistent with information previously provided by Subadviser. Subadviser shall promptly notify the Client of any changes to information pertaining to the Subadviser and stated in the materials described in this Section 6(g).

  • Know-How The term “

  • Notification and Distribution of Materials The Company shall notify the Holders in writing of the effectiveness of the Resale Shelf Registration Statement as soon as practicable, and in any event within one (1) Business Day after the Resale Shelf Registration Statement becomes effective, and shall furnish to them, without charge, such number of copies of the Resale Shelf Registration Statement (including any amendments, supplements and exhibits), the Prospectus contained therein (including each preliminary prospectus and all related amendments and supplements) and any documents incorporated by reference in the Resale Shelf Registration Statement or such other documents as the Holders may reasonably request in order to facilitate the sale of the Registrable Securities in the manner described in the Resale Shelf Registration Statement.

  • Licensed Technology The term "Licensed Technology" shall mean the ------------------- Licensed Patents, plus all improvements thereto developed by Licensor, and all related data, know-how and technology.

  • Transfer of Materials In the event Acceleron exercises its rights pursuant to Section 10.5.1, Celgene shall negotiate in good faith with Acceleron regarding Celgene transferring to Acceleron, at Acceleron’s cost, materials developed under this Agreement in the course of Developing and Commercializing Licensed Compounds or Licensed Products that are directly related to Licensed Compounds or Licensed Products to the extent provided in and in accordance with such agreement.

  • Regulatory Materials (a) Alvogen shall have the sole right to control filing or submission of Regulatory Materials with the Regulatory Agencies in the Territory with respect to Product including the MAA Approval for Product and Regulatory Approvals in the Territory, subject to Section 3.2 and the oversight of and in consultation with the Executive Steering Committee, and [***]Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. shall be responsible for managing all communications and interactions with the Regulatory Agencies in the Territory with respect to Product in the Territory. In all cases, prior to the filing of any Regulatory Materials (including the MAA for Product) for Product with the applicable Regulatory Agency, Alvogen shall provide a copy thereof to Pfenex (through the Executive Steering Committee) for its review and comment. Pfenex shall have fifteen (15) Business Days from the date it receives a copy of any Regulatory Materials with respect to the Product to provide Alvogen with comments regarding such Regulatory Materials, unless the Regulatory Agencies in the Territory or Applicable Law requires that such Regulatory Material(s) be filed on a timeline that does not reasonably permit such advanced notice, in which case Pfenex shall have as much time as is reasonably practicable to provide Alvogen with comments. Alvogen shall consider all such comments in good faith. Alvogen shall, to the extent permitted by Applicable Law, provide Pfenex with (i) reasonable advanced notice (and in no event less than fifteen (15) Business Days’ advance notice whenever feasible) of substantive meetings with any Regulatory Agency in the Territory that are either scheduled with or initiated by or on behalf of Alvogen or its Affiliates, (ii) an opportunity to have a reasonable number (but at least two (2)) representatives participate in all substantive meetings with the Regulatory Agencies in the Territory with respect to Product, and in any case keep Pfenex informed as to all material interactions with the Regulatory Agencies in the Territory with respect to Product, and (iii) a copy of any material documents, information and correspondence submitted to or received from the Regulatory Agencies in the Territory with respect to Product as soon as reasonably practicable.

Time is Money Join Law Insider Premium to draft better contracts faster.